Abgenix, Inc.
Biotech firm prices public offering of convertible senior notes
Published in Lab Business Week, January 23rd, 2005
In addition, the company has granted the initial purchasers of the notes an option to purchase up to an additional $75 million principal amount of notes. The notes will be convertible into common stock of the company at a conversion rate of 78.0153 shares per $1,000 principal amount of notes (representing an initial conversion price of approximately $12.82 per share) and will accrue interest at an annual rate of 1.75%.
The notes will mature in December...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2005-01-23)
More Articles from Lab Business Week
- Abbott
Pharmaceutical firm announces 2005 sales, earnings guidance - Aceto Corporation
Pharmaceuticals distributor reports 30% increase in stock dividend - Adeza Biomedical Corporation
Women's health product maker announces IPO - Apotex, Inc.
$2M donated to faculty of pharmacy at University of Toronto - Array BioPharma, Inc.
Biopharmaceutical firm exercises over-allotment option, completes offering - Arryx, Inc.
Nano-device maker closes on $10M financing - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
